Zydus receives final approval from the USFDA for Baclofen Tablets

Deepthi | Myequity news | Date : 27-11-2018 14:30:00 IST

Zydus Cadila has received the final approval from the USFDA to market Baclofen Tablets (US RLD- Lioresal®), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at Baddi. Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease.  It works by helping to relax the muscles.

About Zydus Cadila:

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research—based pharmaceutical company by 2020

More from Myequity